Behavior
Conduct extensive pain, sensory, motor, and cognitive behavioral testing.
Neurotoxicity and peripheral neuropathy are standard side effects of agents used for chemotherapy. A side effect is peripheral neuropathy and is a limiting factor for dose levels required for anti-tumor effects.
The CIPN in vitro neurodegeneration screening assay utilizes dorsal root ganglion (DRG) neurons from adult rats. Cultures are treated for 5 days with a chemotherapeutic agents followed by treatment with compound. Cultures are stained with beta-tubulin III antibody and measured for neurodegeneration index. The assays are ideal for screening compounds prior to efficacy in in vivo studies.
Chemotherapy treatments often cause neurotoxicity resulting in acute or chronic neuropathic pain for patients. We offer models for understanding the underlying mechanisms of CIPN and evaluating efficacy of potential treatments. Different chemotherapy agents are used to induce neuropathic pain models, which are evaluated by measuring allodynia, hyperalgesia, and biomarkers.
MD Biosciences offers comprehensive in vivo measures and endpoint assessments, delivering robust data packages to support critical research decisions in the evolving landscape of drug development and biomedical research.
Conduct extensive pain, sensory, motor, and cognitive behavioral testing.
Explore inflammatory and pain biomarkers in disease-specific tissues.
Characterize tissue and cellular changes in disease, pain, and neurodegeneration.